NCT00983658View on ClinicalTrials.gov

A Study of huMAb OX40L in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

August 31, 2010

Study Completion Date

January 31, 2011

Conditions
Asthma
Interventions
DRUG

huMAb OX40L

Intravenous repeating dose

DRUG

placebo

Intravenous repeating dose

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY